[go: up one dir, main page]

WO2010011111A3 - 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물 - Google Patents

뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물 Download PDF

Info

Publication number
WO2010011111A3
WO2010011111A3 PCT/KR2009/004148 KR2009004148W WO2010011111A3 WO 2010011111 A3 WO2010011111 A3 WO 2010011111A3 KR 2009004148 W KR2009004148 W KR 2009004148W WO 2010011111 A3 WO2010011111 A3 WO 2010011111A3
Authority
WO
WIPO (PCT)
Prior art keywords
dapsone
life
aging
composition
extension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/004148
Other languages
English (en)
French (fr)
Other versions
WO2010011111A4 (ko
WO2010011111A2 (ko
Inventor
박상철
이준호
조성천
박문철
조윤제
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SNU R&DB Foundation
Original Assignee
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SNU R&DB Foundation filed Critical SNU R&DB Foundation
Priority to EP09800592A priority Critical patent/EP2364698A4/en
Priority to US12/737,553 priority patent/US20110152379A1/en
Publication of WO2010011111A2 publication Critical patent/WO2010011111A2/ko
Publication of WO2010011111A3 publication Critical patent/WO2010011111A3/ko
Publication of WO2010011111A4 publication Critical patent/WO2010011111A4/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 노화조절용 및/또는 수명연장용 조성물에 관한 것이다. 구체적으로는 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물에 관한 것으로, 본 발명의 조성물을 대상에 적용시 노화조절 또는 수명연장효과가 탁월하다. 구체적으로는, 뎁손(DDS)의 처리에 의해 예쁜꼬마선충에서 daf-16에 비의존적으로 수명을 증가시키며, 노화과정을 늦추고, 미토콘드리아 복합체 V 단백질과 세포질 dual oxidase 1(Duox1)의 활성을 감소시켰다. 또한 뎁손에 의해 예쁜꼬마선충에서 산소 소모율을 낮게 유지하여 ROS형성을 감소하는 것으로 확인되었다. 또한 뎁손 처리에 의하여 산화적 스트레스 유도물질인 파라쿼트(paraquat)에 의한 ROS 생성을 줄였으며, 파라쿼트에 의한 민감성도 낮았다. 게다가 구조적인 예측과 분자적, 생화학적 분석을 통하여 피루베이트 키나아제가 뎁손의 목표 물질임을 시사하였다. 또한 인간섬유아세포에서 뎁손에 의해 세포내의 NOX 발현감소 및 저하된 미토콘드리아의 기능회복 효과가 있었다. 이러한 종합적인 결과에 의해 뎁손은 개체수준 및 세포수준에서 수명을 증가시키는 효과가 탁월하다.
PCT/KR2009/004148 2008-07-25 2009-07-24 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물 Ceased WO2010011111A2 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09800592A EP2364698A4 (en) 2008-07-25 2009-07-24 COMPOSITION AGAINST AGING AND / OR LENGTHENING DURATION, CONTAINING DAPSONE AS ACTIVE INGREDIENT
US12/737,553 US20110152379A1 (en) 2008-07-25 2009-07-24 Composition for control of aging and/or extension of life, containing dapsone as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080072762 2008-07-25
KR10-2008-0072762 2008-07-25

Publications (3)

Publication Number Publication Date
WO2010011111A2 WO2010011111A2 (ko) 2010-01-28
WO2010011111A3 true WO2010011111A3 (ko) 2010-03-25
WO2010011111A4 WO2010011111A4 (ko) 2010-05-14

Family

ID=41570754

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004148 Ceased WO2010011111A2 (ko) 2008-07-25 2009-07-24 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물

Country Status (4)

Country Link
US (1) US20110152379A1 (ko)
EP (1) EP2364698A4 (ko)
KR (1) KR20110049808A (ko)
WO (1) WO2010011111A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2538931B1 (en) * 2010-02-26 2016-08-03 University Of Durham Products and methods
KR20130063962A (ko) * 2011-12-07 2013-06-17 가천대학교 산학협력단 디아미노디페닐술폰을 포함하는 골량 저하 질환의 예방 또는 치료용 약학적 조성물
KR101875705B1 (ko) 2011-12-07 2018-07-06 삼성전자주식회사 디아미노디페닐술폰을 포함하는 근육 소모 관련 질환의 예방 또는 치료용 약학적 조성물
MX2016016071A (es) 2014-06-06 2017-07-11 Glaxosmithkline Intellectual Property (No 2) Ltd Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos.
KR102276424B1 (ko) 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
CN112043828A (zh) * 2020-09-23 2020-12-08 南京大学 卟啉porphyrin类物质在光照下延长线虫寿命中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071543A (en) * 1997-06-02 2000-06-06 Cellegy Pharmaceuticals, Inc. Pyridine-thiols reverse mucocutaneous aging
US20050186156A1 (en) * 2002-10-30 2005-08-25 Atrix Laboratories Protectant for UV-induced skin damage
US20070244195A1 (en) * 2004-05-18 2007-10-18 Burkhart Craig N Treatment methods with peroxides and tertiary amines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110294896A1 (en) * 2007-11-07 2011-12-01 Garret John S Topical Treatment With Dapsone In G6PD-Deficient Patients
BRPI0822264A2 (pt) * 2008-02-27 2014-09-30 Allergan Inc Dapsona para tratar rosácea

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071543A (en) * 1997-06-02 2000-06-06 Cellegy Pharmaceuticals, Inc. Pyridine-thiols reverse mucocutaneous aging
US20050186156A1 (en) * 2002-10-30 2005-08-25 Atrix Laboratories Protectant for UV-induced skin damage
US20070244195A1 (en) * 2004-05-18 2007-10-18 Burkhart Craig N Treatment methods with peroxides and tertiary amines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETER G.FORD: "Dapsone", CURRENT PROBLEMS IN DERMATOLOGY, vol. 12, no. 5, 2000, pages 242 - 245, XP005466385 *

Also Published As

Publication number Publication date
EP2364698A2 (en) 2011-09-14
US20110152379A1 (en) 2011-06-23
KR20110049808A (ko) 2011-05-12
WO2010011111A4 (ko) 2010-05-14
EP2364698A4 (en) 2011-09-14
WO2010011111A2 (ko) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2010011111A3 (ko) 뎁손을 유효성분으로 함유하는 노화조절용 및/또는 수명연장용 조성물
Barbier et al. Molecular mechanisms of fluoride toxicity
WO2010082175A3 (en) Kxk-peptide compositions for cosmetic and dermo-pharmaceutic uses
WO2008016664A3 (en) Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2009065857A3 (en) Compositions for reducing oxidative stress and uses thereof
BR112012009490A2 (pt) codec de áudio multimodo e codificação adaptado celp do mesmo
EP2270181A3 (en) DSRNA as insect control agent
WO2012162331A3 (en) Compositions comprising an efficient perfume bloom
CL2007002705A1 (es) Composicion farmaceutica oftalmica autopreservada que comprende 0,04 a 0,9 mm de iones zinc donde la concentracion de aniones tamponantes es menor que 15 mm.
MX2010009198A (es) Fluido de tratamiento con sistema de fractura oxidante y metodo.
WO2010083368A3 (en) Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions
EA200801859A1 (ru) Неводная композиция стабильного витамина "c", способ ее приготовления и применения
WO2008045272A3 (en) Compositions and methods for skin lightening
WO2011156566A3 (en) Chemically stabilized anti-dandruff compositions for use in personal care compositions
TWI319708B (en) Methods and compositions for altering cell fuction
Buico et al. Radical scavenging abilities of fish MT-A and mussel MT-10 metallothionein isoforms: an ESR study
EA201200194A1 (ru) Прозрачная электрохромная система
WO2007090192A3 (en) Stable one-part aqueous tooth whitening composition
WO2006117885A8 (ja) 皮膚外用剤
WO2010107482A3 (en) Germicidal composition
BR112013030068A2 (pt) grânulos de controle biológico estabilizados dispersíveis em água
WO2007053647A3 (en) Cosmetic skincare applications employing mineral-derived tubules for controlled release
WO2011085013A3 (en) Vitamin c composition for use in the prevention and treatment of stretch marks, radiation dermatitis, and other skin conditions and methods of using the same
AU2001258876A1 (en) External application for enhancing the skin permeability of the active components therein
UA108425C2 (uk) Хімічна композиція, яка містить пероксид водню та наноемульсію довголанцюгових спиртів

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09800592

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20117003866

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009800592

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12737553

Country of ref document: US